TY - JOUR
T1 - Mushroom intake and depression
T2 - A population-based study using data from the US National Health and Nutrition Examination Survey (NHANES), 2005–2016
AU - Ba, Djibril M.
AU - Gao, Xiang
AU - Al-Shaar, Laila
AU - Muscat, Joshua E.
AU - Chinchilli, Vernon M.
AU - Beelman, Robert B.
AU - Richie, John P.
N1 - Funding Information:
None.
Publisher Copyright:
© 2021
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Background: Mushrooms contain numerous bioactive compounds that may be associated with reduced anxiety including vitamin B12, nerve growth factor, antioxidants, and anti-inflammatory agents. We hypothesized that mushroom consumption is associated with a lower risk of depression in American adults. Methods: Data from the National Health and Nutrition Examination Survey 2005–2016 was used. Up to two days of 24 h dietary recall were analyzed to assess mushroom intake frequency. Depression was measured using the Patient Health Questionnaire (PHQ-9, score ≥ 10). We used multivariable logistic regression models, adjusting for potential confounding factors. Results: Among 24,699 participants (mean (SE) age: 45.5 (0.3) years), the weighted prevalence of depression was 5.9%. Mushrooms were consumed by 5.2% of participants. Compared with the lowest tertile of mushroom intake, participants in the middle tertile (median intake = 4.9 g/d, number of cases = 16) had lower odds of depression (adjusted OR = 0.31; 95% confidence interval [CI] 0.16, 0.60) while those in the highest tertile did not differ (median intake = 19.6 g/d, adjusted OR = 0.91; 95% CI: 0.47, 1.78, number of cases = 22) (P-trend = 0.42). Limitations: Cross-sectional data and lack of information on specific types of mushrooms consumed. Conclusion: Mushroom consumers had a lower odd of depression. However, we did not observe a dose-response relationship.
AB - Background: Mushrooms contain numerous bioactive compounds that may be associated with reduced anxiety including vitamin B12, nerve growth factor, antioxidants, and anti-inflammatory agents. We hypothesized that mushroom consumption is associated with a lower risk of depression in American adults. Methods: Data from the National Health and Nutrition Examination Survey 2005–2016 was used. Up to two days of 24 h dietary recall were analyzed to assess mushroom intake frequency. Depression was measured using the Patient Health Questionnaire (PHQ-9, score ≥ 10). We used multivariable logistic regression models, adjusting for potential confounding factors. Results: Among 24,699 participants (mean (SE) age: 45.5 (0.3) years), the weighted prevalence of depression was 5.9%. Mushrooms were consumed by 5.2% of participants. Compared with the lowest tertile of mushroom intake, participants in the middle tertile (median intake = 4.9 g/d, number of cases = 16) had lower odds of depression (adjusted OR = 0.31; 95% confidence interval [CI] 0.16, 0.60) while those in the highest tertile did not differ (median intake = 19.6 g/d, adjusted OR = 0.91; 95% CI: 0.47, 1.78, number of cases = 22) (P-trend = 0.42). Limitations: Cross-sectional data and lack of information on specific types of mushrooms consumed. Conclusion: Mushroom consumers had a lower odd of depression. However, we did not observe a dose-response relationship.
UR - http://www.scopus.com/inward/record.url?scp=85111603274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111603274&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2021.07.080
DO - 10.1016/j.jad.2021.07.080
M3 - Article
C2 - 34333177
AN - SCOPUS:85111603274
SN - 0165-0327
VL - 294
SP - 686
EP - 692
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -